Intra-Cellular Therapies (NASDAQ: ITCI) has announced positive topline results from its Phase 3 clinical trial into lumateperone for the treatment of bipolar depression, sending its stock price catapulting higher.
“Our program now has confirmatory evidence of efficacy and a favorable safety and tolerability profile of lumateperone in bipolar depression,” commented Dr Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
The study was conducted in five countries, including the USA, with a total of 529 patients.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
ITCI stated that lumateperone “met the primary endpoint by demonstrating a statistically significant improvement compared to placebo.”
ITCI share price…
The news has resulted in ITCI’s share price climbing over 65% higher to $30.46 per share after closing Tuesday’s trading session at $18.43. Its share price has increased by 54% in the last month.
- PEOPLE WHO READ THIS ALSO VIEWED: TRON (TRX) PRICE SOARS AS MINING PLATFORM GROWS
- TRADE STOCKS WITH IG MARKETS
- COMPARE THESE TOP RATED STOCK BROKERS